TG Therapeutics, Inc. (TGTX) stock
TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/3010% above fair value
$66.12+3.41 (+5.44%)
Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –
TG Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
TG Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $225.80M, up 84.8% year over year. For fiscal 2025 it was $160.22M, up 69.9% from the year before. Over ten years it grew 12.9% a year on average. The highest annual figure on record is $222.58M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $160.22M | +69.9% |
| FY2024 | Dec 31, 2024 | $94.29M | +23.8% |
| FY2023 | Dec 31, 2023 | $76.19M | -39.2% |
| FY2022 | Dec 31, 2022 | $125.35M | -43.7% |
| FY2021 | Dec 31, 2021 | $222.58M | +34.2% |
| FY2020 | Dec 31, 2020 | $165.90M | +7.6% |
| FY2019 | Dec 31, 2019 | $154.18M | -3.3% |
| FY2018 | Dec 31, 2018 | $159.39M | +55.5% |
| FY2017 | Dec 31, 2017 | $102.53M | +48.1% |
| FY2016 | Dec 31, 2016 | $69.23M | +45.1% |
| FY2015 | Dec 31, 2015 | $47.71M | +19.0% |
| FY2014 | Dec 31, 2014 | $40.09M | +193.4% |
| FY2013 | Dec 31, 2013 | $13.66M | -35.0% |
| FY2012 | Dec 31, 2012 | $21.03M | +6325.0% |
| FY2011 | Dec 31, 2011 | $327.28K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $95.34M | +200.0% |
| Q1 FY2026 | Mar 31, 2026 | $48.40M | +4.4% |
| Q4 FY2025 | Dec 31, 2025 | $41.19M | +72.5% |
| Q3 FY2025 | Sep 30, 2025 | $40.88M | +103.0% |
| Q2 FY2025 | Jun 30, 2025 | $31.78M | +81.0% |
| Q1 FY2025 | Mar 31, 2025 | $46.36M | +41.7% |
| Q4 FY2024 | Dec 31, 2024 | $23.87M | +36.8% |
| Q3 FY2024 | Sep 30, 2024 | $20.14M | +36.5% |
| Q2 FY2024 | Jun 30, 2024 | $17.56M | -37.6% |
| Q1 FY2024 | Mar 31, 2024 | $32.72M | +106.2% |
| Q4 FY2023 | Dec 31, 2023 | $17.45M | -41.1% |
| Q3 FY2023 | Sep 30, 2023 | $14.75M | -29.1% |
| Q2 FY2023 | Jun 30, 2023 | $28.12M | +4.6% |
| Q1 FY2023 | Mar 31, 2023 | $15.87M | -67.0% |
| Q4 FY2022 | Dec 31, 2022 | $29.64M | -52.7% |
| Q3 FY2022 | Sep 30, 2022 | $20.80M | -60.0% |
| Q2 FY2022 | Jun 30, 2022 | $26.87M | -40.1% |
| Q1 FY2022 | Mar 31, 2022 | $48.04M | -23.9% |
| Q4 FY2021 | Dec 31, 2021 | $62.65M | +45.8% |
| Q3 FY2021 | Sep 30, 2021 | $51.97M | +3.0% |
| Q2 FY2021 | Jun 30, 2021 | $44.87M | +23.1% |
| Q1 FY2021 | Mar 31, 2021 | $63.09M | +75.2% |
| Q4 FY2020 | Dec 31, 2020 | $42.96M | +38.8% |
| Q3 FY2020 | Sep 30, 2020 | $50.46M | -13.0% |
| Q2 FY2020 | Jun 30, 2020 | $36.45M | +10.9% |
| Q1 FY2020 | Mar 31, 2020 | $36.02M | +11.2% |
| Q4 FY2019 | Dec 31, 2019 | $30.94M | -40.8% |
| Q3 FY2019 | Sep 30, 2019 | $57.99M | +73.6% |
| Q2 FY2019 | Jun 30, 2019 | $32.87M | -15.1% |
| Q1 FY2019 | Mar 31, 2019 | $32.39M | -7.5% |
| Q4 FY2018 | Dec 31, 2018 | $52.28M | +101.1% |
| Q3 FY2018 | Sep 30, 2018 | $33.40M | +23.0% |
| Q2 FY2018 | Jun 30, 2018 | $38.70M | +44.9% |
| Q1 FY2018 | Mar 31, 2018 | $35.02M | +54.4% |
| Q4 FY2017 | Dec 31, 2017 | $26.00M | +16.7% |
| Q3 FY2017 | Sep 30, 2017 | $27.15M | +24.5% |
| Q2 FY2017 | Jun 30, 2017 | $26.71M | – |
| Q1 FY2017 | Mar 31, 2017 | $22.68M | – |
| Q4 FY2016 | Dec 31, 2016 | $22.28M | – |
| Q3 FY2016 | Sep 30, 2016 | $21.80M | – |
See a number that looks wrong?